التفاصيل البيبلوغرافية
| العنوان: |
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. |
| المؤلفون: |
Herbst, Roy S.1 roy.herbst@yale.edu, Baas, Paul2, Dong-Wan Kim3, Felip, Enriqueta4, Pérez-Gracia, José L.5, Ji-Youn Han6, Molina, Julian7, Joo-Hang Kim8, Dubos Arvis, Catherine9, Myung-Ju Ahn10, Majem, Margarita11, Fidler, Mary J.12, de Castro Jr., Gilberto13, Garrido, Marcelo14, Lubiniecki, Gregory M.15, Yue Shentu15, Im, Ellie15, Dolled-Filhart, Marisa15, Garon, Edward B.16, Kim, Dong-Wan17 (AUTHOR) |
| المصدر: |
Lancet. 4/9/2016, Vol. 387 Issue 10027, p1540-1550. 11p. 1 Diagram, 2 Charts, 4 Graphs. |
| مصطلحات موضوعية: |
*RESEARCH, *PATIENT selection, PEMBROLIZUMAB, DOCETAXEL, CANCER treatment, NON-small-cell lung carcinoma, DRUG efficacy, RANDOMIZED controlled trials, ANTIGEN analysis, THERAPEUTIC use of monoclonal antibodies, ANTINEOPLASTIC agents, DRUG therapy, COMPARATIVE studies, DRUG administration, GENES, LUNG cancer, HYDROCARBONS, LUNG tumors, RESEARCH methodology, MEDICAL cooperation, MONOCLONAL antibodies, PROGNOSIS, EVALUATION research, TREATMENT effectiveness, KAPLAN-Meier estimator, THERAPEUTICS |
| مستخلص: |
Background: Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progressive disease. We assessed the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.Methods: We did this randomised, open-label, phase 2/3 study at 202 academic medical centres in 24 countries. Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells were randomly assigned (1:1:1) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, or docetaxel 75 mg/m(2) every 3 weeks. The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50% of tumour cells. We used a threshold for significance of p<0.00825 (one-sided) for the analysis of overall survival and a threshold of p<0.001 for progression-free survival. This trial is registered at ClinicalTrials.gov, number NCT01905657.Findings: Between Aug 28, 2013, and Feb 27, 2015, we enrolled 1034 patients: 345 allocated to pembrolizumab 2 mg/kg, 346 allocated to pembrolizumab 10 mg/kg, and 343 allocated to docetaxel. By Sept 30, 2015, 521 patients had died. In the total population, median overall survival was 10.4 months with pembrolizumab 2 mg/kg, 12.7 months with pembrolizumab 10 mg/kg, and 8.5 months with docetaxel. Overall survival was significantly longer for pembrolizumab 2 mg/kg versus docetaxel (hazard ratio [HR] 0.71, 95% CI 0.58-0.88; p=0.0008) and for pembrolizumab 10 mg/kg versus docetaxel (0.61, 0.49-0.75; p<0.0001). Median progression-free survival was 3.9 months with pembrolizumab 2 mg/kg, 4.0 months with pembrolizumab 10 mg/kg, and 4.0 months with docetaxel, with no significant difference for pembrolizumab 2 mg/kg versus docetaxel (0.88, 0.74-1.05; p=0.07) or for pembrolizumab 10 mg/kg versus docetaxel (HR 0.79, 95% CI 0.66-0.94; p=0.004). Among patients with at least 50% of tumour cells expressing PD-L1, overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel (median 14.9 months vs 8.2 months; HR 0.54, 95% CI 0.38-0.77; p=0.0002) and with pembrolizumab 10 mg/kg than with docetaxel (17.3 months vs 8.2 months; 0.50, 0.36-0.70; p<0.0001). Likewise, for this patient population, progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel (median 5.0 months vs 4.1 months; HR 0.59, 95% CI 0.44-0.78; p=0.0001) and with pembrolizumab 10 mg/kg than with docetaxel (5.2 months vs 4.1 months; 0.59, 0.45-0.78; p<0.0001). Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel (43 [13%] of 339 patients given 2 mg/kg, 55 [16%] of 343 given 10 mg/kg, and 109 [35%] of 309 given docetaxel).Interpretation: Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer. These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection.Funding: Merck & Co. [ABSTRACT FROM AUTHOR] |
|
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Business Source Index |
